Wells Fargo analyst Mohit Bansal maintained a Hold rating on Bristol-Myers Squibb (BMY – Research Report) today and set a price target of $52.00. The company’s shares closed today at $45.06.
Bansal covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Bristol-Myers Squibb, and Amgen. According to TipRanks, Bansal has an average return of 7.5% and a 58.88% success rate on recommended stocks.
Bristol-Myers Squibb has an analyst consensus of Hold, with a price target consensus of $51.71, which is a 14.76% upside from current levels. In a report released on May 6, Bank of America Securities also maintained a Hold rating on the stock with a $55.00 price target.
Based on Bristol-Myers Squibb’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $11.87 billion and a GAAP net loss of $11.91 billion. In comparison, last year the company earned a revenue of $11.34 billion and had a net profit of $2.26 billion
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Bristol-Myers Squibb (BMY) Company Description:
Founded in 1933, New York-based Bristol-Myers Squibb Co. is a global pharmaceutical company, which engages in the development, licensing, manufacturing, distribution, and sale of biopharmaceutical products in several therapeutic areas. These include cancer, HIV/AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis and psychiatric disorders.
Read More on BMY:
- Success Rate as High as 90% for AI-Discovered Drugs
- Bristol Myers announces CheckMate -73L trial did not meet primary endpoint
- Bristol Myers’ application for Opdivo plus Yervoy validated by EMA
- Bristol Myers’ application for subcutaneous nivolumab accepted by FDA
- Editas Medicine, Bristol Myers extend alpha-beta T cell collaboration
